메뉴 건너뛰기




Volumn 23, Issue 10, 2017, Pages 1510-1521

SGLT-2 inhibitors and cardiovascular risk in diabetes mellitus: A comprehensive and critical review of the literature

Author keywords

Albuminuria; Blood pressure; Body weight; Cardiovascular events; Cardiovascular risk; Kidneys function; Lipids; SGLT 2 inhibitors

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALOGLIPTIN; ANTIDIABETIC AGENT; CANAGLIFLOZIN; DAPAGLIFLOZIN; EMPAGLIFLOZIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IPRAGLIFLOZIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LUSEOGLIFLOZIN; METFORMIN; PHLORIZIN; PLACEBO; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA; SULFONYLUREA DERIVATIVE; TOFOGLIFLOZIN; SODIUM GLUCOSE COTRANSPORTER 2;

EID: 85020872544     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612823666170124123927     Document Type: Review
Times cited : (21)

References (125)
  • 1
    • 84978359538 scopus 로고    scopus 로고
    • 7 ed. Brussels, Belgium: International Diabetes Federation
    • International Diabetes Federation. IDF Diabetes Atlas, 7 ed. Brussels, Belgium: International Diabetes Federation 2015.
    • (2015) IDF Diabetes Atlas
  • 2
    • 80051986265 scopus 로고    scopus 로고
    • Globalization of Diabetes: The role of diet, lifestyle, and genes
    • Frank BH. Globalization of Diabetes: the role of diet, lifestyle, and genes. Diab Care 2011; 34: 1249-57.
    • (2011) Diab Care , vol.34 , pp. 1249-1257
    • Frank, B.H.1
  • 3
    • 84912098926 scopus 로고    scopus 로고
    • Type 2 diabetes and cardiovascular disease: Have all risk factors the same strength?
    • Martín-Timón I, Sevillano-Collantes C, Segura-Galindo A, et al. Type 2 diabetes and cardiovascular disease: Have all risk factors the same strength?. World J Diabetes 2014; 5: 444-70.
    • (2014) World J Diabetes , vol.5 , pp. 444-470
    • Martín-Timón, I.1    Sevillano-Collantes, C.2    Segura-Galindo, A.3
  • 4
    • 0027370108 scopus 로고
    • The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus
    • The diabetes control and complications trial research group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1995; 329: 977-986.
    • (1995) N Engl J Med , vol.329 , pp. 977-986
  • 5
    • 84960878943 scopus 로고    scopus 로고
    • Standards of Medical Care in Diabetes-2016: Summary of Revisions
    • American Diabetes Association. Standards of Medical Care in Diabetes-2016: Summary of Revisions. Diab Care 2016; 39: Suppl 1: S4-5.
    • (2016) Diab Care , vol.39 , pp. S4-S5
  • 6
    • 84866268783 scopus 로고    scopus 로고
    • Management of hyperglycaemia in type 2 diabetes: A patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
    • Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diab Care 2012; 35: 1364-79.
    • (2012) Diab Care , vol.35 , pp. 1364-1379
    • Inzucchi, S.E.1    Bergenstal, R.M.2    Buse, J.B.3
  • 7
    • 84885997413 scopus 로고    scopus 로고
    • ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD)
    • Ryden L, Grant PJ, Anker SD, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 2013; 34: 3035-87.
    • (2013) Eur Heart J , vol.34 , pp. 3035-3087
    • Ryden, L.1    Grant, P.J.2    Anker, S.D.3
  • 8
    • 84969296935 scopus 로고    scopus 로고
    • Diabetes and cardiovascular disease: Epidemiology, biological mechanisms, treatment recommendations and future research
    • Leon BM, Maddox TM. Diabetes and cardiovascular disease: Epidemiology, biological mechanisms, treatment recommendations and future research. World J Diabetes 2015; 6: 1246-58.
    • (2015) World J Diabetes , vol.6 , pp. 1246-1258
    • Leon, B.M.1    Maddox, T.M.2
  • 9
    • 84875462788 scopus 로고    scopus 로고
    • Impact of diabetes on cardiovascular disease: An update
    • Matheus AS, Tannus LR, Cobas RA, et al. Impact of diabetes on cardiovascular disease: an update. Int J Hypertens 2013; 2013: 653789.
    • (2013) Int J Hypertens , pp. 2013
    • Matheus, A.S.1    Tannus, L.R.2    Cobas, R.A.3
  • 10
    • 36349001748 scopus 로고    scopus 로고
    • Cardiovascular disease and type 2 diabetes mellitus: A multifaceted symbiosis
    • Johansen OE. Cardiovascular disease and type 2 diabetes mellitus: a multifaceted symbiosis. Scand J Clin Lab Invest 2007; 67: 786-800.
    • (2007) Scand J Clin Lab Invest , vol.67 , pp. 786-800
    • Johansen, O.E.1
  • 11
    • 80054095684 scopus 로고    scopus 로고
    • Diabetes mellitus and cardiovascular disease
    • Li YW, Aronow WS. Diabetes mellitus and cardiovascular disease. J Clinic Exp Cardiol 2011; 2: 2.
    • (2011) J Clinic Exp Cardiol , vol.2 , pp. 2
    • Li, Y.W.1    Aronow, W.S.2
  • 12
    • 38149062075 scopus 로고    scopus 로고
    • Is glycemic control improving in U.S. adults?
    • Hoerger TJ, Segel JE, Gregg EW, et al. Is glycemic control improving in U.S. adults?. Diab Care 2008; 31: 81-6.
    • (2008) Diab Care , vol.31 , pp. 81-86
    • Hoerger, T.J.1    Segel, J.E.2    Gregg, E.W.3
  • 13
    • 79955752170 scopus 로고    scopus 로고
    • Comparative effectiveness and safety of medications for type 2 diabetes: An update including new drugs and 2-drug combinations
    • Bennett WL, Maruthur NM, Singh S, et al. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med 2011; 154: 602-13.
    • (2011) Ann Intern Med , vol.154 , pp. 602-613
    • Bennett, W.L.1    Maruthur, N.M.2    Singh, S.3
  • 14
    • 84901768284 scopus 로고    scopus 로고
    • Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes
    • Holman RR, Sourij H, Califf RM. Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes. Lancet 2014; 383: 2008-17.
    • (2014) Lancet , vol.383 , pp. 2008-2017
    • Holman, R.R.1    Sourij, H.2    Califf, R.M.3
  • 15
    • 84861098920 scopus 로고    scopus 로고
    • Efficacy and Safety of SGLT2 Inhibitors in the Treatment of Type 2 Diabetes Mellitus
    • Abdul-Ghani MA, Norton L, DeFronzo RA. Efficacy and Safety of SGLT2 Inhibitors in the Treatment of Type 2 Diabetes Mellitus. Curr Diab Rep 2012; 12: 230-38.
    • (2012) Curr Diab Rep , vol.12 , pp. 230-238
    • Abdul-Ghani, M.A.1    Norton, L.2    Defronzo, R.A.3
  • 16
    • 84928911112 scopus 로고    scopus 로고
    • Sodium-glucose co-transporter 2 (SGLT2) inhibitors: A growing class of antidiabetic agents
    • Vivian EM. Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agents. Drugs Context 2014; 3: 212-64
    • (2014) Drugs Context , vol.3 , pp. 212-264
    • Vivian, E.M.1
  • 17
    • 84944800184 scopus 로고    scopus 로고
    • Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes
    • Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373: 2117-28.
    • (2015) N Engl J Med , vol.373 , pp. 2117-2128
    • Zinman, B.1    Wanner, C.2    Lachin, J.M.3
  • 18
    • 84855525536 scopus 로고    scopus 로고
    • Cardiovascular risk of oral antidiabetic drugs: Current evidence and regulatory requirements for new drugs
    • Panicker GK, Karnad DR, Salvi V, et al. Cardiovascular risk of oral antidiabetic drugs: current evidence and regulatory requirements for new drugs. J Assoc Physicians India 2012; 60: 56-61.
    • (2012) J Assoc Physicians India , vol.60 , pp. 56-61
    • Panicker, G.K.1    Karnad, D.R.2    Salvi, V.3
  • 19
    • 0032511566 scopus 로고    scopus 로고
    • Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
    • UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-65.
    • (1998) Lancet , vol.352 , pp. 854-865
  • 20
    • 77954988618 scopus 로고    scopus 로고
    • Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone
    • Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, et al. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA 2010; 304: 411-8.
    • (2010) JAMA , vol.304 , pp. 411-418
    • Graham, D.J.1    Ouellet-Hellstrom, R.2    Macurdy, T.E.3
  • 21
    • 84880919064 scopus 로고    scopus 로고
    • Results of a reevaluation of cardiovascular outcomes in the RECORD trial
    • Mahaffey KW, Hafley G, Dickerson S, et al. Results of a reevaluation of cardiovascular outcomes in the RECORD trial. Am Heart J 2013; 166: 240-9.
    • (2013) Am Heart J , vol.166 , pp. 240-249
    • Mahaffey, K.W.1    Hafley, G.2    Dickerson, S.3
  • 22
    • 84937053742 scopus 로고    scopus 로고
    • Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes
    • Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015; 373: 232-42.
    • (2015) N Engl J Med , vol.373 , pp. 232-242
    • Green, J.B.1    Bethel, M.A.2    Armstrong, P.W.3
  • 23
    • 84930085787 scopus 로고    scopus 로고
    • Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: A multicentre, randomised, doubleblind trial
    • Zannad F, Cannon CP, Cushman WC, et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, doubleblind trial. Lancet 2015; 385: 2067-76.
    • (2015) Lancet , vol.385 , pp. 2067-2076
    • Zannad, F.1    Cannon, C.P.2    Cushman, W.C.3
  • 24
    • 84880688845 scopus 로고    scopus 로고
    • GLP-1 receptor agonists: Effects on cardiovascular risk reduction
    • Lorber, D. GLP-1 receptor agonists: effects on cardiovascular risk reduction. Cardiovasc Therap 2013; 31: 238-49.
    • (2013) Cardiovasc Therap , vol.31 , pp. 238-249
    • Lorber, D.1
  • 25
    • 85014593796 scopus 로고    scopus 로고
    • Potential cardiovascular effects of the glucagonlike peptide-1 receptor agonists
    • Chilton RJ. Potential cardiovascular effects of the glucagonlike peptide-1 receptor agonists. J Diabetes Metab 2015; 6: 483.
    • (2015) J Diabetes Metab , vol.6 , pp. 483
    • Chilton, R.J.1
  • 26
    • 83655193529 scopus 로고    scopus 로고
    • The role of the kidneys in glucose homeostasis: A new path towards normalizing glycaemia
    • DeFronzo RA, Davidson JA, Del Prato S. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diab Obes and Metab 2011; 14: 5-14.
    • (2011) Diab Obes and Metab , vol.14 , pp. 5-14
    • Defronzo, R.A.1    Davidson, J.A.2    Del Prato, S.3
  • 27
    • 78651406659 scopus 로고    scopus 로고
    • SGLT2 mediates glucose reabsorption in the early proximal tubule
    • Vallon V, Platt KA, Cunard R, et al. SGLT2 mediates glucose reabsorption in the early proximal tubule. J Am Soc Nephrol 201; 22: 104-12.
    • J am Soc Nephrol 201 , vol.22 , pp. 104-112
    • Vallon, V.1    Platt, K.A.2    Cunard, R.3
  • 28
    • 0028044629 scopus 로고
    • The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose
    • Kanai Y, Lee WS, You G, et al. The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose. J Clin Invest 1994; 93: 397-404.
    • (1994) J Clin Invest , vol.93 , pp. 397-404
    • Kanai, Y.1    Lee, W.S.2    You, G.3
  • 29
    • 33846023326 scopus 로고    scopus 로고
    • Active sugar transport in health and disease
    • Wright E, Hirayama B, Loo D. Active sugar transport in health and disease. J Intern Med 2007; 261: 32-43.
    • (2007) J Intern Med , vol.261 , pp. 32-43
    • Wright, E.1    Hirayama, B.2    Loo, D.3
  • 30
    • 0032146567 scopus 로고    scopus 로고
    • Abnormal renal and hepatic glucose metabolism in type 2 diabetes mellitus
    • Meyer C, Stumvoll M, Nadkarni V, et al. Abnormal renal and hepatic glucose metabolism in type 2 diabetes mellitus. J Clin Invest 1998; 102: 619-24.
    • (1998) J Clin Invest , vol.102 , pp. 619-624
    • Meyer, C.1    Stumvoll, M.2    Nadkarni, V.3
  • 31
    • 8544226262 scopus 로고    scopus 로고
    • Abnormal renal, hepatic, and muscle glucose metabolism following glucose ingestion in type 2 diabetes
    • Meyer C, Woerle HJ, Dostou JM, et al. Abnormal renal, hepatic, and muscle glucose metabolism following glucose ingestion in type 2 diabetes. Am J Physiol Endocrinol Metab 2004; 287: E1049-56.
    • (2004) Am J Physiol Endocrinol Metab , vol.287 , pp. E1049-E1056
    • Meyer, C.1    Woerle, H.J.2    Dostou, J.M.3
  • 32
    • 0015122757 scopus 로고
    • Maximum tubular reabsorption capacity for glucose and renal hemodynamcis during rapid hypertonic glucose infusion in normal and diabetic subjects
    • Mogensen CE. Maximum tubular reabsorption capacity for glucose and renal hemodynamcis during rapid hypertonic glucose infusion in normal and diabetic subjects. Scand J Clin Lab Invest 1971; 28: 101-9.
    • (1971) Scand J Clin Lab Invest , vol.28 , pp. 101-109
    • Mogensen, C.E.1
  • 33
    • 84929354073 scopus 로고    scopus 로고
    • Sodium-glucose cotransport inhibitors: Mechanisms, metabolic effects and implications for the treatment of diabetic patients with chronic kidney disease
    • Vlotides G, Mertens PR. Sodium-glucose cotransport inhibitors: mechanisms, metabolic effects and implications for the treatment of diabetic patients with chronic kidney disease. Nephrol Dial Transplant 2014; pii: gfu299.
    • (2014) Nephrol Dial Transplant
    • Vlotides, G.1    Mertens, P.R.2
  • 34
    • 33644688031 scopus 로고    scopus 로고
    • Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes
    • Rahmoune H, Thompson P, Ward J, Smith C, Hong G, Brown J. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes 2005; 54: 3427-34.
    • (2005) Diabetes , vol.54 , pp. 3427-3434
    • Rahmoune, H.1    Thompson, P.2    Ward, J.3    Smith, C.4    Hong, G.5    Brown, J.6
  • 35
    • 1242272759 scopus 로고    scopus 로고
    • The sodium/glucose contrasport family SLC5
    • Wright EM; Turk E. The sodium/glucose contrasport family SLC5. Pflugers Arch 2004; 447: 510-8.
    • (2004) Pflugers Arch , vol.447 , pp. 510-518
    • Wright, E.M.1    Turk, E.2
  • 37
    • 0000298609 scopus 로고
    • Phlorizin as a competitive inhibitor of the active transport of sugars by hamster small intestine, in vitro
    • Alvarado F, Crane RK. Phlorizin as a competitive inhibitor of the active transport of sugars by hamster small intestine, in vitro. Biochim Biophys Acta 1962; 56: 170-2.
    • (1962) Biochim Biophys Acta , vol.56 , pp. 170-172
    • Alvarado, F.1    Crane, R.K.2
  • 38
    • 0023275573 scopus 로고
    • Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats
    • Rossetti L, Smith D, Shulman GI, et al. Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest 1987; 79: 1510-5.
    • (1987) J Clin Invest , vol.79 , pp. 1510-1515
    • Rossetti, L.1    Smith, D.2    Shulman, G.I.3
  • 39
    • 0023571397 scopus 로고
    • Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats
    • Rossetti L, Shulman GI, Zawalich W, et al. Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats. J Clin Invest 1987; 80: 1037-44.
    • (1987) J Clin Invest , vol.80 , pp. 1037-1044
    • Rossetti, L.1    Shulman, G.I.2    Zawalich, W.3
  • 41
    • 84888346204 scopus 로고    scopus 로고
    • SGLT-2 inhibitors and their potential in the treatment of diabetes
    • Rosenwasser RF, Sultan S, Sutton D, et al. SGLT-2 inhibitors and their potential in the treatment of diabetes. Diabetes Metab Syndr Obes 2013; 6: 453-67.
    • (2013) Diabetes Metab Syndr Obes , vol.6 , pp. 453-467
    • Rosenwasser, R.F.1    Sultan, S.2    Sutton, D.3
  • 42
    • 84923448295 scopus 로고    scopus 로고
    • SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials
    • Inzucchi SE, Zinman B, Wanner C, et al. SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials. Diab Vasc Dis Res 2015; 12: 90-100.
    • (2015) Diab Vasc Dis Res , vol.12 , pp. 90-100
    • Inzucchi, S.E.1    Zinman, B.2    Wanner, C.3
  • 43
    • 0034641568 scopus 로고    scopus 로고
    • Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study
    • Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405-12.
    • (2000) BMJ , vol.321 , pp. 405-412
    • Stratton, I.M.1    Adler, A.I.2    Neil, H.A.3
  • 44
    • 84948716657 scopus 로고    scopus 로고
    • Efficacy and safety of sodiumglucose cotransporter 2 inhibitors in type 2 diabetes: A metaanalysis of randomized controlled trials for 1 to 2 years
    • Liu XY, Zhang N, Chen R, et al. Efficacy and safety of sodiumglucose cotransporter 2 inhibitors in type 2 diabetes: a metaanalysis of randomized controlled trials for 1 to 2 years. J Diabetes Complications. 2015; 29: 1295-303.
    • (2015) J Diabetes Complications , vol.29 , pp. 1295-1303
    • Liu, X.Y.1    Zhang, N.2    Chen, R.3
  • 45
    • 84895484977 scopus 로고    scopus 로고
    • Dapagliflozin treatment for type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials
    • Zhang M, Zhang L, Wu B, et al. Dapagliflozin treatment for type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetes Metab Res Rev 2014; 30: 204-21.
    • (2014) Diabetes Metab Res Rev , vol.30 , pp. 204-221
    • Zhang, M.1    Zhang, L.2    Wu, B.3
  • 46
    • 84898789114 scopus 로고    scopus 로고
    • Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: A systematic review and network meta-analysis
    • Goring S, Hawkins N, Wygant G, et al. Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis. Diabetes Obes Metab 2014; 16: n433-42.
    • (2014) Diabetes Obes Metab , vol.16 , pp. n433-n442
    • Goring, S.1    Hawkins, N.2    Wygant, G.3
  • 47
    • 80155124676 scopus 로고    scopus 로고
    • Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: A randomized, 52-week, double-blind, active-controlled noninferiority trial
    • Nauck MA, Del Prato S, Meier JJ, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care 2011; 34: 2015-22.
    • (2011) Diabetes Care , vol.34 , pp. 2015-2022
    • Nauck, M.A.1    Del Prato, S.2    Meier, J.J.3
  • 48
    • 77953857048 scopus 로고    scopus 로고
    • Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: A randomised, double-blind, placebocontrolled trial
    • Bailey CJ, Gross JL, Pieters A, et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebocontrolled trial. Lancet 2010; 375: 2223-33.
    • (2010) Lancet , vol.375 , pp. 2223-2233
    • Bailey, C.J.1    Gross, J.L.2    Pieters, A.3
  • 49
    • 77956921439 scopus 로고    scopus 로고
    • Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: A randomized, double-blind, placebo-controlled, phase 3 trial
    • Ferrannini E, Ramos SJ, Salsali A, et al. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 2010; 33: 2217-24.
    • (2010) Diabetes Care , vol.33 , pp. 2217-2224
    • Ferrannini, E.1    Ramos, S.J.2    Salsali, A.3
  • 50
    • 80052524011 scopus 로고    scopus 로고
    • Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: A randomized, 24-week, double-blind, placebo-controlled trial
    • Strojek K, Yoon KH, Hruba V, et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab 2011; 13: 928-38.
    • (2011) Diabetes Obes Metab , vol.13 , pp. 928-938
    • Strojek, K.1    Yoon, K.H.2    Hruba, V.3
  • 51
    • 84912533839 scopus 로고    scopus 로고
    • Efficacy and safety of empagliflozin for type 2 diabetes: A systematic review and metaanalysis
    • Liakos A, Karagiannis T, Athanasiadou E, et al. Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and metaanalysis. Diabetes Obes Metab 2014; 16: 984-93.
    • (2014) Diabetes Obes Metab , vol.16 , pp. 984-993
    • Liakos, A.1    Karagiannis, T.2    Athanasiadou, E.3
  • 52
    • 84885954870 scopus 로고    scopus 로고
    • Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: A randomised, double-blind, placebo-controlled, phase 3 trial
    • Roden M, Weng J, Eilbracht J, et al. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol 2013; 1: 208-19.
    • (2013) Lancet Diabetes Endocrinol , vol.1 , pp. 208-219
    • Roden, M.1    Weng, J.2    Eilbracht, J.3
  • 53
    • 84901455931 scopus 로고    scopus 로고
    • Empagliflozin as add-on to metformin in patients with type 2 diabetes: A 24-week, randomized, double-blind, placebo-controlled trial
    • Häring HU, Merker L, Seewaldt-Becker E, et al. Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 2014; 37: 1650-9.
    • (2014) Diabetes Care , vol.37 , pp. 1650-1659
    • Häring, H.U.1    Merker, L.2    Seewaldt-Becker, E.3
  • 54
    • 84885952950 scopus 로고    scopus 로고
    • Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: A 24-week, randomized, double-blind, placebo-controlled trial
    • Häring HU, Merker L, Seewaldt-Becker E, et al. Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 2013; 36: 3396-404.
    • (2013) Diabetes Care , vol.36 , pp. 3396-3404
    • Häring, H.U.1    Merker, L.2    Seewaldt-Becker, E.3
  • 55
    • 84892477577 scopus 로고    scopus 로고
    • Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: A 24-week, randomized, placebo-controlled trial
    • Kovacs CS, Seshiah V, Swallow R, et al. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab 2014; 16: 147-58.
    • (2014) Diabetes Obes Metab , vol.16 , pp. 147-158
    • Kovacs, C.S.1    Seshiah, V.2    Swallow, R.3
  • 56
    • 84903511385 scopus 로고    scopus 로고
    • Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes
    • Rosenstock J, Jelaska A, Frappin G, et al. Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes. Diabetes Care 2014; 37: 1815-23.
    • (2014) Diabetes Care , vol.37 , pp. 1815-1823
    • Rosenstock, J.1    Jelaska, A.2    Frappin, G.3
  • 57
    • 84929676338 scopus 로고    scopus 로고
    • Efficacy and safety of canagliflozin in subjects with type 2 diabetes: Systematic review and metaanalysis
    • Yang XP, Lai D, Zhong XY, et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes: systematic review and metaanalysis. Eur J Clin Pharmacol 2014; 70: 1149-58.
    • (2014) Eur J Clin Pharmacol , vol.70 , pp. 1149-1158
    • Yang, X.P.1    Lai, D.2    Zhong, X.Y.3
  • 58
    • 84887997289 scopus 로고    scopus 로고
    • Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: A randomised trial
    • Lavalle-Gonzalez FJ, Januszewicz A, Davidson J, et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia 2013; 56: 2582-92.
    • (2013) Diabetologia , vol.56 , pp. 2582-2592
    • Lavalle-Gonzalez, F.J.1    Januszewicz, A.2    Davidson, J.3
  • 59
    • 84891784200 scopus 로고    scopus 로고
    • Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: A 52-week randomized trial
    • Schernthaner G, Gross JL, A Rosenstock, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care 2013; 36: 2508-15.
    • (2013) Diabetes Care , vol.36 , pp. 2508-2515
    • Schernthaner, G.1    Gross, J.L.2    Rosenstock, A.3
  • 60
    • 84880543926 scopus 로고    scopus 로고
    • Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: A randomized trial
    • Bode B, Stenlof K, Sullivan D, et al. Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial. Hosp Pract (1995). 2013; 41: 72-84.
    • (2013) Hosp Pract (1995) , vol.41 , pp. 72-84
    • Bode, B.1    Stenlof, K.2    Sullivan, D.3
  • 61
    • 84874291673 scopus 로고    scopus 로고
    • Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise
    • Stenlof K, Cefalu WT, Kim KA, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab 2013; 15: b372-82.
    • (2013) Diabetes Obes Metab , vol.15 , pp. b372-b382
    • Stenlof, K.1    Cefalu, W.T.2    Kim, K.A.3
  • 62
    • 84922108911 scopus 로고    scopus 로고
    • Ipragliflozin in combination with metformin for the treatment of Japanese patients with type 2diabetes: ILLUMINATE, a randomized, double-blind, placebocontrolled study
    • Kashiwagi A, Kazuta K, Goto K, et al. Ipragliflozin in combination with metformin for the treatment of Japanese patients with type 2diabetes: ILLUMINATE, a randomized, double-blind, placebocontrolled study. Diabetes Obes Metab 2015; 17: 304-8.
    • (2015) Diabetes Obes Metab , vol.17 , pp. 304-308
    • Kashiwagi, A.1    Kazuta, K.2    Goto, K.3
  • 63
    • 84921328874 scopus 로고    scopus 로고
    • A randomized, double-blind, placebo-controlled study on long-term efficacy and safety of ipragliflozin treatment in patients with type 2 diabetes mellitus and renal impairment: Results of the long-term ASP1941 safety evaluation in patients with type 2 diabetes with renal impairment (LANTERN) study
    • Kashiwagi A, Takahashi H, Ishikawa H, et al. A randomized, double-blind, placebo-controlled study on long-term efficacy and safety of ipragliflozin treatment in patients with type 2 diabetes mellitus and renal impairment: results of the long-term ASP1941 safety evaluation in patients with type 2 diabetes with renal impairment (LANTERN) study. Diabetes Obes Metab 2015; 17: 152-60.
    • (2015) Diabetes Obes Metab , vol.17 , pp. 152-160
    • Kashiwagi, A.1    Takahashi, H.2    Ishikawa, H.3
  • 64
    • 84876344111 scopus 로고    scopus 로고
    • Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled onmetformin: A dose-finding study
    • Wilding JP, Ferrannini E, Fonseca VA, et al. Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled onmetformin: a dose-finding study. Diabetes Obes Metab 2013; 15: 403-9.
    • (2013) Diabetes Obes Metab , vol.15 , pp. 403-409
    • Wilding, J.P.1    Ferrannini, E.2    Fonseca, V.A.3
  • 65
    • 84902245089 scopus 로고    scopus 로고
    • Efficacy and safety of luseogliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: A 12-week, randomized, placebo-controlled, phase II study
    • Seino Y, Sasaki T, Fukatsu A, et al. Efficacy and safety of luseogliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, placebo-controlled, phase II study. Curr Med Res Opin 2014; 30: 1219-30.
    • (2014) Curr Med Res Opin , vol.30 , pp. 1219-1230
    • Seino, Y.1    Sasaki, T.2    Fukatsu, A.3
  • 66
    • 84903557735 scopus 로고    scopus 로고
    • Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetesmellitus: A randomized, double-blind, placebo-controlled, phase 3 study
    • Seino Y, Sasaki T, Fukatsu A, et al. Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetesmellitus: a randomized, double-blind, placebo-controlled, phase 3 study. Curr Med Res Opin 2014; 30: 1245-55.
    • (2014) Curr Med Res Opin , vol.30 , pp. 1245-1255
    • Seino, Y.1    Sasaki, T.2    Fukatsu, A.3
  • 67
    • 84899558137 scopus 로고    scopus 로고
    • Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: A combined Phase 2 and 3 randomized, placebo-controlled, doubleblind, parallel-group comparative study
    • Kaku K, Watada H, Iwamoto Y, et al. Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, doubleblind, parallel-group comparative study. Cardiovasc Diabetol 2014; 13: 65.
    • (2014) Cardiovasc Diabetol , vol.13 , pp. 65
    • Kaku, K.1    Watada, H.2    Iwamoto, Y.3
  • 68
    • 84902294790 scopus 로고    scopus 로고
    • A novel and selective SGLT2 inhibitor, tofogliflozin improves glycaemic control and lowers body weight in patients with type 2 diabetes mellitus
    • Ikeda S, Takano Y, Cynshi O, et al. A novel and selective SGLT2 inhibitor, tofogliflozin improves glycaemic control and lowers body weight in patients with type 2 diabetes mellitus. Diabetologia 2012; 55 (suppl 1): S1-S538.
    • (2012) Diabetologia , vol.55 , pp. SS1-S538
    • Ikeda, S.1    Takano, Y.2    Cynshi, O.3
  • 69
    • 0034641550 scopus 로고    scopus 로고
    • Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): Prospective observational study
    • Adler AI, Stratton IM, Neil HA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000; 321: 412-9.
    • (2000) BMJ , vol.321 , pp. 412-419
    • Adler, A.I.1    Stratton, I.M.2    Neil, H.A.3
  • 70
    • 84943187885 scopus 로고    scopus 로고
    • Sodium-glucose cotransporter-2 inhibitors and blood pressure decrease: A valuable effect of a novel antidiabetic class?
    • Imprialos KP, Sarafidis PA, Karagiannis AI. Sodium-glucose cotransporter-2 inhibitors and blood pressure decrease: a valuable effect of a novel antidiabetic class? J Hypertens 2015; 33: 2185-97.
    • (2015) J Hypertens , vol.33 , pp. 2185-2197
    • Imprialos, K.P.1    Sarafidis, P.A.2    Karagiannis, A.I.3
  • 71
    • 77649116361 scopus 로고    scopus 로고
    • Diuretics in clinical practice. Part I: Mechanisms of action, pharmacological effects and clinical indications of diuretic compounds
    • Sarafidis PA, Georgianos PI, Lasaridis AN. Diuretics in clinical practice. Part I: mechanisms of action, pharmacological effects and clinical indications of diuretic compounds. Expert Opin Drug Saf 2010; 9: 243-57.
    • (2010) Expert Opin Drug Saf , vol.9 , pp. 243-257
    • Sarafidis, P.A.1    Georgianos, P.I.2    Lasaridis, A.N.3
  • 72
    • 33845497759 scopus 로고    scopus 로고
    • Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome
    • Bakris G, Molitch M, Hewkin A, et al. Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Diab Care 2006; 29: 2592-7.
    • (2006) Diab Care , vol.29 , pp. 2592-2597
    • Bakris, G.1    Molitch, M.2    Hewkin, A.3
  • 73
    • 84898854471 scopus 로고    scopus 로고
    • Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: A systematic review and meta-analysis
    • Baker WL, Smyth LR, Riche DM, et al. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J Am Soc Hypertens 2014; 8: 262-75.
    • (2014) J am Soc Hypertens , vol.8 , pp. 262-275
    • Baker, W.L.1    Smyth, L.R.2    Riche, D.M.3
  • 74
    • 84920544038 scopus 로고    scopus 로고
    • Prevalence of whitecoat and masked hypertension in national and international registries
    • Gorostidi M, Vinyoles E, Banegas JR, et al. Prevalence of whitecoat and masked hypertension in national and international registries. Hypertens Res 2015; 38: 1-7.
    • (2015) Hypertens Res , vol.38 , pp. 1-7
    • Gorostidi, M.1    Vinyoles, E.2    Banegas, J.R.3
  • 75
    • 84859895463 scopus 로고    scopus 로고
    • Should ambulatory blood pressure monitoring be mandatory for future studies in resistant hypertension: A perspective
    • Doumas M, Anyfanti P, Bakris G. Should ambulatory blood pressure monitoring be mandatory for future studies in resistant hypertension: a perspective. J Hypertens 2012; 30: 874-6.
    • (2012) J Hypertens , vol.30 , pp. 874-876
    • Doumas, M.1    Anyfanti, P.2    Bakris, G.3
  • 76
    • 0038581685 scopus 로고    scopus 로고
    • Office versus Ambulatory Pressure Study Investigators. Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension
    • Clement DL, De Buyzere ML, De Bacquer DA, et al. Office versus Ambulatory Pressure Study Investigators. Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. N Engl J Med 2003; 348: 2407-15.
    • (2003) N Engl J Med , vol.348 , pp. 2407-2415
    • Clement, D.L.1    de Buyzere, M.L.2    de Bacquer, D.A.3
  • 77
    • 54449099978 scopus 로고    scopus 로고
    • Noninvasive 24-h ambulatory blood pressure and cardiovascular disease: A systematic review and meta-analysis
    • Conen D, Bamberg F. Noninvasive 24-h ambulatory blood pressure and cardiovascular disease: a systematic review and meta-analysis. J Hypertens 2008; 26: 1290-9.
    • (2008) J Hypertens , vol.26 , pp. 1290-1299
    • Conen, D.1    Bamberg, F.2
  • 78
    • 34848883594 scopus 로고    scopus 로고
    • Prognostic accuracy of day vs. Night ambulatory blood pressure: A cohort study
    • Boggia J, Li Y, Thijs L, et al. Prognostic accuracy of day vs. night ambulatory blood pressure: a cohort study. Lancet 2007; 370: 1219-29.
    • (2007) Lancet , vol.370 , pp. 1219-1229
    • Boggia, J.1    Li, Y.2    Thijs, L.3
  • 79
    • 84958125420 scopus 로고    scopus 로고
    • Effects of dapagliflozin on blood pressure in hypertensive diabetic patients on reninangiotensin system blockade
    • Weber MA, Mansfield TA, Alessi F, et al. Effects of dapagliflozin on blood pressure in hypertensive diabetic patients on reninangiotensin system blockade. Blood Press 2016; 25: 93-103.
    • (2016) Blood Press , vol.25 , pp. 93-103
    • Weber, M.A.1    Mansfield, T.A.2    Alessi, F.3
  • 80
    • 84915738767 scopus 로고    scopus 로고
    • Effects of dapagliflozin on blood pressure in diabetic patients with hypertension inadequately controlled by a renin-angiotensin system blocker
    • Weber MA, Mansfield TA, Alessi F, et al. Effects of dapagliflozin on blood pressure in diabetic patients with hypertension inadequately controlled by a renin-angiotensin system blocker. Circulation 2013; 128: A13144.
    • (2013) Circulation , vol.128
    • Weber, M.A.1    Mansfield, T.A.2    Alessi, F.3
  • 81
    • 84959460390 scopus 로고    scopus 로고
    • Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: A randomised, double-blind, placebo-controlled, phase 3 study
    • Weber MA, Mansfield TA, Cain VA, et al. Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Diabetes Endocrinol 2016; 4: 211-20.
    • (2016) Lancet Diabetes Endocrinol , vol.4 , pp. 211-220
    • Weber, M.A.1    Mansfield, T.A.2    Cain, V.A.3
  • 82
    • 84915738766 scopus 로고    scopus 로고
    • Dapagliflozin for reduction of blood pressure in diabetic patients inadequately controlled with combination antihypertensive regimen
    • Weber MA, Mansfield TA, T’joen C, et al. Dapagliflozin for reduction of blood pressure in diabetic patients inadequately controlled with combination antihypertensive regimen. Circulation 2013; 128: A13165.
    • (2013) Circulation , vol.128
    • Weber, M.A.1    Mansfield, T.A.2    T’Joen, C.3
  • 83
    • 84880850027 scopus 로고    scopus 로고
    • Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
    • Lambers-Heerspink HJ, De Zeeuw D, Wie L, et al. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab 2013; 15: 853-62.
    • (2013) Diabetes Obes Metab , vol.15 , pp. 853-862
    • Lambers-Heerspink, H.J.1    de Zeeuw, D.2    Wie, L.3
  • 84
    • 84953638180 scopus 로고    scopus 로고
    • Reductions in mean 24-hour ambulatory blood pressure after 6-week treatment with canagliflozin in patients with type 2 diabetes mellitus and hypertension
    • Townsend RR, Machin I, Ren J, et al. Reductions in mean 24-hour ambulatory blood pressure after 6-week treatment with canagliflozin in patients with type 2 diabetes mellitus and hypertension. J Clin Hypertens (Greenwich) 2016; 18: 43-52.
    • (2016) J Clin Hypertens (Greenwich) , vol.18 , pp. 43-52
    • Townsend, R.R.1    Machin, I.2    Ren, J.3
  • 85
    • 84928196614 scopus 로고    scopus 로고
    • Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension
    • Tikkanen I, Narko K, Zeller C, et al. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care 2015; 38: 420-8.
    • (2015) Diabetes Care , vol.38 , pp. 420-428
    • Tikkanen, I.1    Narko, K.2    Zeller, C.3
  • 86
    • 84882251091 scopus 로고    scopus 로고
    • Sodium glucose cotransporter 2 inhibitors for type 2 diabetes: A systematic review and meta-analysis
    • Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodium glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med 2013; 159: 262-74.
    • (2013) Ann Intern Med , vol.159 , pp. 262-274
    • Vasilakou, D.1    Karagiannis, T.2    Athanasiadou, E.3
  • 87
    • 84921811268 scopus 로고    scopus 로고
    • Energy balance following sodium-glucose co-transporter-2 (SGLT2) inhibition
    • OP 01 SGLT2 inhibitors
    • Ferrannini G, Hach T, Crowe S, et al et al. Energy balance following sodium-glucose co-transporter-2 (SGLT2) inhibition. Diabetologia 2014; OP#3 (OP 01 SGLT2 inhibitors).
    • (2014) Diabetologia , Issue.3
    • Ferrannini, G.1    Hach, T.2    Crowe, S.3
  • 89
    • 84897447957 scopus 로고    scopus 로고
    • Canagliflozin: Effects in overweight and obese subjects without diabetes mellitus
    • Bays HE, Weinstein R, Law G, et al. Canagliflozin: effects in overweight and obese subjects without diabetes mellitus. Obesity (Silver Spring) 2014; 22: 1042-9.
    • (2014) Obesity (Silver Spring) , vol.22 , pp. 1042-1049
    • Bays, H.E.1    Weinstein, R.2    Law, G.3
  • 90
    • 82955194914 scopus 로고    scopus 로고
    • Thinking beyond traditional cardiovascular risk factors: The role of arterial stiffness in targeting residual risk
    • Katsiki N, Koumaras C, Athyros VG, et al. Thinking beyond traditional cardiovascular risk factors: the role of arterial stiffness in targeting residual risk. Angiology 2012; 63: 9-11.
    • (2012) Angiology , vol.63 , pp. 9-11
    • Katsiki, N.1    Koumaras, C.2    Athyros, V.G.3
  • 91
    • 84943542801 scopus 로고    scopus 로고
    • Arterial stiffness and emerging biomarkers: Still a long journey to go
    • Doumas M, Papademetriou V, Athyros V, et al. Arterial stiffness and emerging biomarkers: still a long journey to go. Angiology 2015; 66: 901-3.
    • (2015) Angiology , vol.66 , pp. 901-903
    • Doumas, M.1    Papademetriou, V.2    Athyros, V.3
  • 92
    • 77949557153 scopus 로고    scopus 로고
    • Prediction of cardiovascular events and all cause mortality with arterial stiffness: A systematic review and meta-analysis
    • Vlachopoulos C, Aznaouridis K, Stefanidis C. Prediction of cardiovascular events and all cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol 2010; 55: 1318-27.
    • (2010) J am Coll Cardiol , vol.55 , pp. 1318-1327
    • Vlachopoulos, C.1    Aznaouridis, K.2    Stefanidis, C.3
  • 93
    • 84892959743 scopus 로고    scopus 로고
    • The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus
    • Cherney DZ, Perkins BA, Soleymanlou N, et al. The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovasc Diabetol 2014; 13: 28.
    • (2014) Cardiovasc Diabetol , vol.13 , pp. 28
    • Cherney, D.Z.1    Perkins, B.A.2    Soleymanlou, N.3
  • 94
    • 84903528312 scopus 로고    scopus 로고
    • Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice
    • Terami N, Ogawa D, Tachibana H, et al. Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice. PLoS ONE 2014; 9: e100777.
    • (2014) Plos ONE , pp. 9
    • Terami, N.1    Ogawa, D.2    Tachibana, H.3
  • 95
    • 0015122757 scopus 로고
    • Maximum tubular reabsorption capacity for glucose and renal hemodynamics during rapid hypertonic glucose infusion in normal and diabetic subjects
    • Mogensen CE. Maximum tubular reabsorption capacity for glucose and renal hemodynamics during rapid hypertonic glucose infusion in normal and diabetic subjects. Scand J Clin Lab Invest 1971; 28: 101-9.
    • (1971) Scand J Clin Lab Invest , vol.28 , pp. 101-109
    • Mogensen, C.E.1
  • 96
    • 33644688031 scopus 로고    scopus 로고
    • Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes
    • Rahmoune H, Thompson PW, Ward JM, et al. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes 2005; 54: 3427-34.
    • (2005) Diabetes , vol.54 , pp. 3427-3434
    • Rahmoune, H.1    Thompson, P.W.2    Ward, J.M.3
  • 97
    • 84872400230 scopus 로고    scopus 로고
    • Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus
    • Vallon V, Rose M, Gerasimova M, et al. Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus. Am J Physiol Renal Physiol 2013; 304: F156-67.
    • (2013) Am J Physiol Renal Physiol , vol.304 , pp. F156-F167
    • Vallon, V.1    Rose, M.2    Gerasimova, M.3
  • 98
    • 84255185190 scopus 로고    scopus 로고
    • Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat
    • Thomson S, Rieg T, Miracle C, et al. Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat. Am J Physiol Regul Integr Comp Physiol 2012; 302: R75-83.
    • (2012) Am J Physiol Regul Integr Comp Physiol , vol.302 , pp. R75-R83
    • Thomson, S.1    Rieg, T.2    Miracle, C.3
  • 99
    • 85020530779 scopus 로고    scopus 로고
    • Nephroprotection by Hypoglycemic Agents: Do We Have Supporting Data?
    • Gorriz JL, Nieto J, Navarro-Gonzalez JF, et al. Nephroprotection by Hypoglycemic Agents: Do We Have Supporting Data? J Clin Med 2015; 4: 1866-89.
    • (2015) J Clin Med , vol.4 , pp. 1866-1889
    • Gorriz, J.L.1    Nieto, J.2    Navarro-Gonzalez, J.F.3
  • 100
    • 84878060305 scopus 로고    scopus 로고
    • Effects of a new SGLT2 inhibitor, luseogliflozin, on diabetic nephropathy in T2DN rats
    • Kojima N, Williams J, Takahashi T, et al. Effects of a new SGLT2 inhibitor, luseogliflozin, on diabetic nephropathy in T2DN rats. J Pharmacol Exp Ther 2013; 345: 464-72.
    • (2013) J Pharmacol Exp Ther , vol.345 , pp. 464-472
    • Kojima, N.1    Williams, J.2    Takahashi, T.3
  • 101
    • 84892588641 scopus 로고    scopus 로고
    • SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic akita mice
    • Vallon V, Gerasimova M, Rose M, et al. SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic akita mice. Am J Physiol Renal Physiol 2014; 306: F194-204.
    • (2014) Am J Physiol Renal Physiol , vol.306 , pp. F194-F204
    • Vallon, V.1    Gerasimova, M.2    Rose, M.3
  • 102
    • 84905238756 scopus 로고    scopus 로고
    • The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension
    • Gembardt F, Bartaun C, Jarzebska N, et al. The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension. Am J Physiol Renal Physiol 2014; 307: F317-25.
    • (2014) Am J Physiol Renal Physiol , vol.307 , pp. F317-F325
    • Gembardt, F.1    Bartaun, C.2    Jarzebska, N.3
  • 103
    • 84897394040 scopus 로고    scopus 로고
    • Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control
    • Kohan DE, Fioretto P, Tang W, et al. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney International 2014; 85: 962-71.
    • (2014) Kidney International , vol.85 , pp. 962-971
    • Kohan, D.E.1    Fioretto, P.2    Tang, W.3
  • 104
    • 84876311251 scopus 로고    scopus 로고
    • Efficacy and safety of canagliflozin in subject swith type 2 diabetes and chronic kidney disease
    • Yale JF, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin in subject swith type 2 diabetes and chronic kidney disease. Diabetes Obesity and Metabolism 2013; 15: 463-73.
    • (2013) Diabetes Obesity and Metabolism , vol.15 , pp. 463-473
    • Yale, J.F.1    Bakris, G.2    Cariou, B.3
  • 105
    • 84912527805 scopus 로고    scopus 로고
    • Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease
    • Yale JF, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes Obesity and Metabolism 2014; 16: 1016-27.
    • (2014) Diabetes Obesity and Metabolism , vol.16 , pp. 1016-1027
    • Yale, J.F.1    Bakris, G.2    Cariou, B.3
  • 106
    • 84899961819 scopus 로고    scopus 로고
    • Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: A randomised, double-blind, placebo-controlled trial
    • Barnett AH, Mithal A, Manassie J, et al. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2014; 2: 369-84.
    • (2014) Lancet Diabetes Endocrinol , vol.2 , pp. 369-384
    • Barnett, A.H.1    Mithal, A.2    Manassie, J.3
  • 107
    • 79957858617 scopus 로고    scopus 로고
    • Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality: A collaborative metaanalysis of high-risk population cohorts
    • van der Velde M, Matsushita K, Coresh J, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality: A collaborative metaanalysis of high-risk population cohorts. Kidney Int 2011; 79: 1341-52
    • (2011) Kidney Int , vol.79 , pp. 1341-1352
    • van Der Velde, M.1    Matsushita, K.2    Coresh, J.3
  • 108
    • 79960205374 scopus 로고    scopus 로고
    • ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)
    • Catapano AL, Reiner Z, De Backer G, et al. ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 2011; 217: 3-46.
    • (2011) Atherosclerosis , vol.217 , pp. 3-46
    • Catapano, A.L.1    Reiner, Z.2    de Backer, G.3
  • 109
    • 84923524414 scopus 로고    scopus 로고
    • Changes in lipid profiles of patients with type 2 diabetes mellitus on dapagliflozin therapy
    • Hardy E, Ptanszynska A, de Bruin TWA, et al. Changes in lipid profiles of patients with type 2 diabetes mellitus on dapagliflozin therapy. Diabetologia 2013; Suppl. #947: 61.
    • (2013) Diabetologia , Issue.947 , pp. 61
    • Hardy, E.1    Ptanszynska, A.2    de Bruin, T.3
  • 110
    • 84899960517 scopus 로고    scopus 로고
    • Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: A pooled analysis of clinical studies
    • Sinclair A, Bode B, Harris S, et al. Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. BMC Endocr Disord 2014; 14: 37.
    • (2014) BMC Endocr Disord , vol.14 , pp. 37
    • Sinclair, A.1    Bode, B.2    Harris, S.3
  • 111
    • 84899941589 scopus 로고    scopus 로고
    • Empagliflozin improves glycaemic parameters and cardiovascular risk factors in patients with type 2 diabetes: Pooled data from four pivotal phase III trials
    • Hach T, Gerich J, Salsali A, et al. Empagliflozin improves glycaemic parameters and cardiovascular risk factors in patients with type 2 diabetes: pooled data from four pivotal phase III trials. Diabetes 2013; 62 (Suppl 1): LB19.
    • (2013) Diabetes , vol.62
    • Hach, T.1    Gerich, J.2    Salsali, A.3
  • 112
    • 33750606061 scopus 로고    scopus 로고
    • Long-term follow-up of patients with NAFLD and elevated liver enzymes
    • Ekstedt M, Franzen LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44: 865-73
    • (2006) Hepatology , vol.44 , pp. 865-873
    • Ekstedt, M.1    Franzen, L.E.2    Mathiesen, U.L.3
  • 113
    • 34547673500 scopus 로고    scopus 로고
    • Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients
    • Targher G, Bertolini L, Rodella S, et al. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabetes Care 2007; 30: 2119-21.
    • (2007) Diabetes Care , vol.30 , pp. 2119-2121
    • Targher, G.1    Bertolini, L.2    Rodella, S.3
  • 114
    • 84947786115 scopus 로고    scopus 로고
    • Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus
    • Qiang S, Nakatsu Y, Seno Y, et al. Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus. Diabetol Metab Syndr 2015; 7: 104.
    • (2015) Diabetol Metab Syndr , vol.7 , pp. 104
    • Qiang, S.1    Nakatsu, Y.2    Seno, Y.3
  • 115
    • 84962210716 scopus 로고    scopus 로고
    • Ipragliflozin, a sodiumglucose cotransporter 2 inhibitor, ameliorates the development of liver fibrosis in diabetic Otsuka Long-Evans Tokushima fatty rats
    • [Epub ahead of print]
    • Nishimura N, Kitade M, Noguchi R, et al. Ipragliflozin, a sodiumglucose cotransporter 2 inhibitor, ameliorates the development of liver fibrosis in diabetic Otsuka Long-Evans Tokushima fatty rats. J Gastroenterol 2016; [Epub ahead of print]
    • (2016) J Gastroenterol
    • Nishimura, N.1    Kitade, M.2    Noguchi, R.3
  • 116
    • 84953791948 scopus 로고    scopus 로고
    • The selective SGLT2 inhibitor ipragliflozin has a therapeutic effect on nonalcoholic steatohepatitis in mice
    • Honda Y, Imajo K, Kato T, et al. The selective SGLT2 inhibitor ipragliflozin has a therapeutic effect on nonalcoholic steatohepatitis in mice. PLoS One 2016; 11: e0146337.
    • (2016) Plos One , pp. 11
    • Honda, Y.1    Imajo, K.2    Kato, T.3
  • 117
    • 84975698839 scopus 로고    scopus 로고
    • Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: Results of the EMPA-REG OUTCOMER trial
    • Fitchett D, Zinman B, Wanner C, et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOMER trial. Eur Heart J 2016; 37: 1526-34.
    • (2016) Eur Heart J , vol.37 , pp. 1526-1534
    • Fitchett, D.1    Zinman, B.2    Wanner, C.3
  • 118
    • 85020860519 scopus 로고    scopus 로고
    • FDA Briefing Document NDA 202293. Dapagliflozin tablets 5 and 10 mg, Food and Drug Administration. Available from: (http://www.fda.gov/DOWNLOADS/ADVISORYCOMMITTEES/COMMITTEESMEETINGMATERIALS/DRUGS/ENDOCRINOLOGICANDMETABOLICDRUGSADVISORYCOMMITTEE/UCM262994.bPDF).
    • Dapagliflozin Tablets 5 and 10 Mg, Food and Drug Administration
  • 119
    • 72649106871 scopus 로고    scopus 로고
    • FDA briefing material NDA 204042. Food and Drug Administation. Available from: (http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM334550.pdf)
    • Food and Drug Administation
  • 120
    • 84962613532 scopus 로고    scopus 로고
    • Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: A systematic review and meta-analysis
    • Wu JH, Foote C, Blomster J, et al. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 2016; 4: 411-9.
    • (2016) Lancet Diabetes Endocrinol , vol.4 , pp. 411-419
    • Wu, J.H.1    Foote, C.2    Blomster, J.3
  • 121
    • 85005950931 scopus 로고    scopus 로고
    • Stroke paradox with SGLT-2 inhibitors: A play of chance or a viscosity-mediated reality?
    • Imprialos KP, Boutari C, Stavropoulos K, et al. Stroke paradox with SGLT-2 inhibitors: a play of chance or a viscosity-mediated reality?. J Neurol Neurosurg Psychiatry. 2016. Article in press. DOI: 10.1136/jnnp-2016-314704.
    • (2016) J Neurol Neurosurg Psychiatry
    • Imprialos, K.P.1    Boutari, C.2    Stavropoulos, K.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.